271 related articles for article (PubMed ID: 10769285)
1. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart.
Cheung PY; Sawicki G; Wozniak M; Wang W; Radomski MW; Schulz R
Circulation; 2000 Apr; 101(15):1833-9. PubMed ID: 10769285
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting matrix metalloproteinase-2 reduces protein release into coronary effluent from isolated rat hearts during ischemia-reperfusion.
Fert-Bober J; Leon H; Sawicka J; Basran RS; Devon RM; Schulz R; Sawicki G
Basic Res Cardiol; 2008 Sep; 103(5):431-43. PubMed ID: 18512095
[TBL] [Abstract][Full Text] [Related]
3. Influence of ischemia/reperfusion and modulation of PI3K/Akt kinase pathway on matrix metalloproteinase-2 in rat hearts.
Spániková A; Ivanová M; Matejíková J; Ravingerová T; Barancík M
Gen Physiol Biophys; 2010 Mar; 29(1):31-40. PubMed ID: 20371878
[TBL] [Abstract][Full Text] [Related]
4. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2.
Lalu MM; Csonka C; Giricz Z; Csont T; Schulz R; Ferdinandy P
Biochem Biophys Res Commun; 2002 Aug; 296(4):937-41. PubMed ID: 12200138
[TBL] [Abstract][Full Text] [Related]
5. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2.
Sawicki G; Leon H; Sawicka J; Sariahmetoglu M; Schulze CJ; Scott PG; Szczesna-Cordary D; Schulz R
Circulation; 2005 Jul; 112(4):544-52. PubMed ID: 16027249
[TBL] [Abstract][Full Text] [Related]
6. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial [correction of myoctardial] ischemia-reperfusion injury.
Schulze CJ; Wang W; Suarez-Pinzon WL; Sawicka J; Sawicki G; Schulz R
Circulation; 2003 May; 107(19):2487-92. PubMed ID: 12707244
[TBL] [Abstract][Full Text] [Related]
7. Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury.
Chan BYH; Roczkowsky A; Cho WJ; Poirier M; Lee TYT; Mahmud Z; Schulz R
Basic Res Cardiol; 2019 Sep; 114(6):42. PubMed ID: 31506724
[TBL] [Abstract][Full Text] [Related]
8. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2.
Wang W; Sawicki G; Schulz R
Cardiovasc Res; 2002 Jan; 53(1):165-74. PubMed ID: 11744025
[TBL] [Abstract][Full Text] [Related]
9. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/reperfusion injury.
Ali MA; Cho WJ; Hudson B; Kassiri Z; Granzier H; Schulz R
Circulation; 2010 Nov; 122(20):2039-47. PubMed ID: 21041693
[TBL] [Abstract][Full Text] [Related]
10. Duration of ischaemia determines matrix metalloproteinase-2 activation in the reperfused rabbit heart.
Prasan AM; McCarron HC; White MY; McLennan SV; Tchen AS; Hambly BD; Jeremy RW
Proteomics; 2002 Sep; 2(9):1204-10. PubMed ID: 12362337
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation status of matrix metalloproteinase 2 in myocardial ischaemia-reperfusion injury.
Sariahmetoglu M; Skrzypiec-Spring M; Youssef N; Jacob-Ferreira AL; Sawicka J; Holmes C; Sawicki G; Schulz R
Heart; 2012 Apr; 98(8):656-62. PubMed ID: 22397940
[TBL] [Abstract][Full Text] [Related]
12. Doxycycline reduces cardiac matrix metalloproteinase-2 activity but does not ameliorate myocardial dysfunction during reperfusion in coronary artery bypass patients undergoing cardiopulmonary bypass.
Schulze CJ; Castro MM; Kandasamy AD; Cena J; Bryden C; Wang SH; Koshal A; Tsuyuki RT; Finegan BA; Schulz R
Crit Care Med; 2013 Nov; 41(11):2512-20. PubMed ID: 23928836
[TBL] [Abstract][Full Text] [Related]
13. Nuclear matrix metalloproteinase-2 in the cardiomyocyte and the ischemic-reperfused heart.
Baghirova S; Hughes BG; Poirier M; Kondo MY; Schulz R
J Mol Cell Cardiol; 2016 May; 94():153-161. PubMed ID: 27079252
[TBL] [Abstract][Full Text] [Related]
14. Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia-reperfusion injury.
Bassiouni W; Valencia R; Mahmud Z; Seubert JM; Schulz R
Basic Res Cardiol; 2023 Jul; 118(1):29. PubMed ID: 37495895
[TBL] [Abstract][Full Text] [Related]
15. Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.
Roczkowsky A; Chan BYH; Lee TYT; Mahmud Z; Hartley B; Julien O; Armanious G; Young HS; Schulz R
Cardiovasc Res; 2020 Apr; 116(5):1021-1031. PubMed ID: 31373602
[TBL] [Abstract][Full Text] [Related]
16. Role of matrix metalloproteinase-2 in the cardioprotective effect of ischaemic postconditioning.
Donato M; D'Annunzio V; Buchholz B; Miksztowicz V; Carrión CL; Valdez LB; Zaobornyj T; Schreier L; Wikinski R; Boveris A; Berg G; Gelpi RJ
Exp Physiol; 2010 Feb; 95(2):274-81. PubMed ID: 19880538
[TBL] [Abstract][Full Text] [Related]
17. Matrix metalloproteinase-2 degrades the cytoskeletal protein alpha-actinin in peroxynitrite mediated myocardial injury.
Sung MM; Schulz CG; Wang W; Sawicki G; Bautista-López NL; Schulz R
J Mol Cell Cardiol; 2007 Oct; 43(4):429-36. PubMed ID: 17854826
[TBL] [Abstract][Full Text] [Related]
18. Combined subthreshold dose inhibition of myosin light chain phosphorylation and MMP-2 activity provides cardioprotection from ischaemic/reperfusion injury in isolated rat heart.
Cadete VJ; Sawicka J; Bekar LK; Sawicki G
Br J Pharmacol; 2013 Sep; 170(2):380-90. PubMed ID: 23822644
[TBL] [Abstract][Full Text] [Related]
19. Ischemia/reperfusion-induced myosin light chain 1 phosphorylation increases its degradation by matrix metalloproteinase 2.
Cadete VJ; Sawicka J; Jaswal JS; Lopaschuk GD; Schulz R; Szczesna-Cordary D; Sawicki G
FEBS J; 2012 Jul; 279(13):2444-54. PubMed ID: 22564771
[TBL] [Abstract][Full Text] [Related]
20. Matrix Metalloproteinase-2 Inhibition in Acute Ischemia-Reperfusion Heart Injury-Cardioprotective Properties of Carvedilol.
Skrzypiec-Spring M; Urbaniak J; Sapa-Wojciechowska A; Pietkiewicz J; Orda A; Karolko B; Danielewicz R; Bil-Lula I; Woźniak M; Schulz R; Szeląg A
Pharmaceuticals (Basel); 2021 Dec; 14(12):. PubMed ID: 34959676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
